Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) 
signaling are being explored as prophylactic treatments for migraine. Erenumab 
(AMG 334) is the first potent, selective, and competitive human mAb antagonist 
of the CGRP receptor. We report the data from two phase I studies assessing the 
safety, pharmacokinetics (PK), and pharmacodynamics of single and multiple 
administrations of erenumab in healthy subjects and patients with migraine. The 
results indicate that the PK profile of erenumab is nonlinear from 1 mg to 70 mg 
and the linear portion of the clearance from 70 mg to 210 mg is consistent with 
other human immunoglobulin G2 antibodies. Single doses of erenumab resulted in 
>75% inhibition of capsaicin-induced dermal blood flow, with no apparent 
dose-dependency for erenumab ≥21 mg. Erenumab was generally well tolerated, with 
an acceptable safety profile, supporting further clinical development of 
erenumab for migraine prevention.